Edwards Lifesciences (EW) exec Lippis sells 620 shares after exercising stock options

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daniel J. Lippis reported an option exercise and related share sale under a pre-planned Rule 10b5-1 trading plan. On 2026-05-18, he exercised employee stock options for 620 shares of common stock at an exercise price of $72.68 per share and sold 620 shares in an open-market transaction at $81.14 per share.

Following these transactions, Lippis directly held about 40,410.9103 shares of common stock and 6,190 employee stock options exercisable into common shares. Because the activity was executed pursuant to a Rule 10b5-1 plan adopted on February 13, 2026, the timing appears routine rather than discretionary.

Insights

Equity compensation analyst

Routine option exercise-and-sell under a pre-set 10b5-1 plan with modest net share reduction.

Daniel J. Lippis, a senior executive at Edwards Lifesciences Corp, exercised employee stock options for 620 common shares at an exercise price of $72.68 and sold 620 shares at $81.14. This is a classic exercise-and-sell pattern that converts option value into cash while realizing the spread between market and exercise price.

The filing notes that these transactions were executed under a Rule 10b5-1 trading plan adopted on February 13, 2026, indicating they were pre-scheduled rather than opportunistic. After the trades, Lippis still directly owned 40,410.9103 common shares and held 6,190 employee stock options expiring on May 6, 2027. Given the small scale relative to his remaining holdings and the pre-planned nature, this appears to be routine portfolio and compensation management rather than a strong directional signal.

Insider Trade Summary 10b5-1

Net Seller: 620 shares ($50,307)

Net Sell 3 txns

Insider Lippis Daniel J.

Role CVP, TAVR

Sold 620 shs ($50K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	620	$0.00	--
Exercise	Common Stock	620	$72.68	$45K
Sale	Common Stock	620	$81.14	$50K

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 6,190 shares (Direct, null); Common Stock — 41,030.91 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 620 shares Sale price: $81.14 per share Options exercised: 620 shares +3 more

6 metrics

Shares sold 620 shares Open-market sale of common stock at $81.14 per share on May 18, 2026

Sale price $81.14 per share Price received for 620 common shares sold in open market

Options exercised 620 shares Employee stock options exercised into common stock on May 18, 2026

Option exercise price $72.68 per share Exercise price for employee stock options converted into 620 common shares

Common shares held after 40,410.9103 shares Direct common stock holdings following the transactions

Options remaining 6,190 options Employee stock options outstanding after exercise, expiring May 6, 2027

Key Terms

Rule 10b5-1 trading plan, open-market sale, Employee Stock Option (Right to Acquire), derivative security

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Employee Stock Option (Right to Acquire) financial

"security_title: Employee Stock Option (Right to Acquire)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		M(1)		620	A	$72.68	41,030.9103	D
Common Stock	05/18/2026		S(1)		620	D	$81.14	40,410.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$72.68	05/18/2026		M			620	05/07/2021	05/06/2027	Common Stock	620	$0.0000	6,190	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Edwards Lifesciences (EW) executive Daniel Lippis report?

Daniel J. Lippis reported an option exercise and related share sale. He exercised employee stock options for 620 common shares at an exercise price of $72.68 and sold 620 shares at $81.14, reflecting a routine compensation-related transaction.

How many Edwards Lifesciences (EW) shares did Daniel Lippis sell and at what price?

Daniel Lippis sold 620 shares of Edwards Lifesciences common stock in an open-market transaction at $81.14 per share. This sale was paired with an option exercise for the same number of shares on the same date, indicating an exercise-and-sell pattern.

What options did Daniel Lippis exercise in his latest Edwards Lifesciences (EW) Form 4?

He exercised employee stock options covering 620 shares of Edwards Lifesciences common stock at an exercise price of $72.68 per share. These options are part of a larger grant, with 6,190 options remaining outstanding and expiring on May 6, 2027.

How many Edwards Lifesciences (EW) shares does Daniel Lippis own after the reported transactions?

After the reported transactions, Daniel Lippis directly owns 40,410.9103 shares of Edwards Lifesciences common stock. This figure reflects his holdings following the option exercise of 620 shares and the sale of 620 shares on May 18, 2026.

Was the Edwards Lifesciences (EW) insider trade by Daniel Lippis under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on February 13, 2026. Such plans pre-schedule trades, so the timing is generally considered routine rather than discretionary or event-driven.

What derivative holdings remain for Daniel Lippis after this Edwards Lifesciences (EW) filing?

Following the transactions, Daniel Lippis holds 6,190 employee stock options, each representing the right to acquire one share of common stock at an exercise price of $72.68. These options are scheduled to expire on May 6, 2027, according to the filing details.